Background. The limited access to virological monitoring in developing countries is a major weakness of the current antiretroviral treatment (ART) strategy in these settings. We conducted a large cross-sectional study in Burkina Faso, Cameroon, Cote d'Ivoire, Senegal, Togo, Thailand, and Vietnam to assess virological failure and drug resistance mutations (DRMs) after 12 or 24 months of ART.
these settings. Over the past 10 years, almost a 20-fold increase in treatment access has been observed in low-and middleincome countries, and about 14 million life-years have been gained since 1995 [1] . A sustained access to treatment is thus essential to revert the trend of morbidity and mortality due to human immunodeficiency virus (HIV) infection and AIDS and represents a critical challenge in the current context of reduced funding. Almost all low-and middle-income countries have adopted the WHO public health approach [2, 3] as the standard for antiretroviral (ARV) delivery and monitoring, although doubts exist about the long-term efficacy of this simplified strategy, which has several caveats, compared with the reference approach used in resource-rich countries. Major concerns are associated with the adoption of clinical and/or immunological criteria only for treatment initiation and switch and with the use of low-genetic-barrier drugs that may favor the rapid emergence, spread, and transmission of resistant viruses.
Early results from ART programs in developing countries have been promising, showing virological outcomes similar to those obtained in industrialized settings [4, 5] . However, the growing expansion of these programs has revealed high rates of treatment failure in many countries, with reports of virological failure rates of >20% after 12 months [6] [7] [8] or 24 months of ART [9] [10] [11] . Rapid development of resistance to low-geneticbarrier ARVs, which is the case for certain nucleoside reversetranscriptase inhibitors (NRTIs) and non-NRTIs (NNRTIs) is also a major concern, and the 2 most frequently selected mutations, M184V and K103N, can critically impair current firstline regimens [12, 13] . Cross-resistance and accumulation of resistance mutations in patients who receive a failing regimen for a long period have also been highlighted and represent a major threat for ongoing and future treatment options [14, 15] . Recent studies have shown that transmission of drug-resistant strains is increasing with the widespread distribution of ARVs in these settings [16] [17] [18] , with the potential of reducing the efficacy of available first-line regimens [19] . Studies assessing treatment outcome in the developing world have also reported significant issues with patient adherence, with a high proportion of virological failures associated with poor adherence to treatment [8, 20] . The recent WHO amendment to perform viral load testing, when available, is not feasible in most areas [3] , because of the prohibitive costs and operational difficulties. The question of routine access to viral load is critical, considering the known limitations of clinical and immunological monitoring [11, 21, 22] . Strategies to address these weaknesses are thus to be defined, not only to improve the quality and success of current first-line ART, but also to preserve the efficacy of second-and third-line therapies in developing countries.
In this large and multicountry study, we sought to determine the efficacy of current ART regimens and pending challenges in developing countries by assessing first-line treatment outcome among patients attending ART services in 5 countries in subSaharan Africa and 2 countries in Southeast Asia.
MATERIAL AND METHODS

Study Sites and Population
From October 2009 through December 2011, we implemented a cross-sectional evaluation of treatment outcomes among patients participating in ART services that administered antiretroviral agents and monitored treatment according to national recommendations. Data from the following 7 countries were evaluated: Burkina Faso, Cameroon, Cote d'Ivoire, Senegal, Togo, Thailand, and Vietnam. All of these countries initiated ART programs around [2002] [2003] [2004] , and all adopted the WHO public health policy for ART scale-up. Study sites are listed in Table 1 . Two criteria were considered for site selection: (1) the site must respect the national policy for ART delivery and monitoring; (2) the site must have been active for at least 3 years, to enable recruitment of patients who had received ART for at least 24 months (M24). The number of participants recruited in each site was calculated to ensure a statistical precision of ±0.05 for the obtained virological failure rates.
Study participants were consecutively enrolled HIV type 1 (HIV-1)-infected adults (age, ≥18 years). All were attending healthcare services for their routine medical visit and initiated ART 10-14 months (the M12 group) or 22-26 months (the M24 group) earlier at a unique treatment site. All were still receiving a first-line regimen and reported no history of previous exposure to ARVs. Infections with divergent HIV strains, such as HIV-1 group O or HIV type 2, were excluded. In Cote d'Ivoire, the study implementation varied slightly from the main protocol. We used data from a similar study that was conducted in the country from January 2007 to February 2009 [8] . The main difference was population size, since the initial Cote d'Ivoire study included more patients (n = 942), but recruitment criteria were similar.
Data and Sample Collection
We used questionnaires and on-site medical records to collect epidemiological and demographic information. In clinics, whole blood was collected from eligible patients and sent within 6 hours to designated national laboratories (Table 1) . Upon reception, blood samples were centrifuged, and plasma specimens were aliquoted and stored at -70°C for further HIV-1 RNA quantification and drug resistance genotyping.
Virological Analyses
Viral load tests were performed using methods currently used in the countries: Nuclisens EasyQ (bioMérieux, Marcy l'Etoile, France) in Togo; RealTime m2000rt (Abbott Pack, IL) in Cameroon, Senegal, and Thailand; and generic G2 real-time PCR (Biocentric, Bandol, France) in Burkina Faso, Cote d'Ivoire, and Vietnam. In accordance with WHO recommendations for monitoring studies in developing countries [22b] , we considered virological failure as a viral load of ≥1000 copies/mL. Thus, samples with a viral load of ≥1000 copies/mL underwent a drug resistance genotyping covering the pol region that spans the entire protease gene and at least the first 240 codons of the reverse transcriptase gene. Genotyping assays were performed either locally, using available methods (Viroseq HIV- 
Quality Assessment
Quality assessment included on-site supervisory visits and retesting of a subset of samples (10% for each site) in the reference laboratories in France for viral load analyses. Any significant discrepancy between site and reference laboratory results was investigated and corrective actions initiated.
Data Management and Statistical Analysis
Data entry was performed using an online information system creation tool, Voozanoo (EpiConcept, 2009 
Ethical Considerations
Only participants who provided written informed consent were recruited, and anonymous identifiers were assigned to each patient to guarantee confidentiality. National or local ethics committees of all participating countries approved the study.
Sequence Accession Numbers
The newly reported protease and reverse transcriptase sequences are available in GenBank under the following accession numbers: KC349986 to KC350418.
RESULTS
Population Characteristics
We recruited 3935 patients, of whom 2060 were in the M12 group and 1875 were in the M24 group. None of the participants belonged to both groups. The number of participants recruited in the M12 group ranged between 262 in Senegal and 327 in Togo, whereas the number in the M24 group ranged from 168 to 315 in Senegal and Togo, respectively. Overall, we observed no significant difference between M12 and M24 participants regarding demographic and clinical characteristics (Table 2) . Indeed, in both groups the sex ratios were similar, with women representing about 70% of participants in the African countries and males representing the majority of participants in the Asia countries. in both groups (P < .001). First-line regimens at treatment initiation in the 7 countries predominantly included stavudine or zidovudine plus lamivudine plus nevirapine or efavirenz, and a limited number of patients received tenofovir instead of stavudine or zidovudine in Burkina Faso, Senegal, and Thailand. Other regimens included abacavir and didanosine as NRTIs but no protease inhibitor (PI) and were limited to a few patients (Table 2) . Several patients reported drug substitutions not resulting in treatment line change. In the majority of cases, the reasons of these changes were not specified, but the most frequently reported reasons included toxicity/intolerance (233 patients overall), drug stock-outs (64 patients), and voluntary interruption (37 patients).
Virological Failure
Overall, we found similar frequencies of virological failure between patients recruited at M12 (11.1% [228/2060]) and those enrolled at M24 (12.4% [232/1875]). However, the detailed analyses revealed significant heterogeneity across countries (Table 3 ). In clinics that participated in Burkina Faso and Thailand (group A), we found low levels of virological failure (≤5%) in both the M12 and M24 groups. In clinics in Cameroon, Senegal, and Vietnam (group B), the frequency of virological failure varied from 9.2% to 13.9% in the 2 patient groups, while at Cote d'Ivoire and Togo sites (group C), the frequency of virological failure varied from 18% to 20% in M12 patients and from 14% to 26% in M24 patients (Table 3) . Comparison of these 3 levels of virological failure via χ 2 analysis showed a significant difference between groups A, B, and C (P < .001) at month 12 and at month 24. The median viral load in patients who did not respond to ART ranged between 4.1 log 10 copies/ mL (IQR, 3.4-4.7 log 10 copies/mL) and 5.2 log 10 copies/mL (IQR, 4.5-5.9 log 10 copies/mL) for M12 patients and between 4.3 log 10 copies/mL (IQR, 3.6-4.8 log 10 copies/mL) and 4.8 log 10 copies/mL (IQR, 4.0-5.6 log 10 copies/mL) in the M24 group. Among patients in both groups who did not respond, 10%-50% had a viral load between 1000 and 5000 copies/mL, indicating that using the current WHO threshold for failure (ie, 5000 copies/mL) could lead to significant misclassification of patients for whom ART is failing. Only 1 HIV-1 variant, CRF01_AE, was found in Asian patients from Thailand and Vietnam, while a complex spectrum of HIV-1 subtypes and CRFs was observed in African areas. Overall, CRF02_AG predominated in African countries. The other main subtypes/CRFs included CRF06_cpx, CRF09_cpx, CRF11_cpx, CRF22_01A1, CRF36_cpx, CRF43_02G, A1, A3, C, D, F2, G, H, unclassifiable, and unique recombinant strains ( Table 3) .
Frequency of Drug Resistance
Among patients with a viral load of ≥1000 copies/mL and successful viral sequencing, 71.0% (149/210) carried a resistant virus in the M12 group, and this proportion increased to 86.1% (192/223) in the M24 group. We observed a similar trend in sites where the frequency of virological failure was >5%: 57.1% (16/28) (25/29) , respectively, in Vietnam. Detailed analyses of DRMs showed no major PI resistance mutation, and the few observed cases of resistance to PIs resulted from the combination of the following accessory mutations: L10I/V, I15V, K20R/I, M36I, I62V, I64M, H69K, and L89M, common to non-B HIV-1 viruses (Table 3) .
Resistance to NRTIs only was rare (3 of 149 and 2 of 192 patients in the M12 and M24 groups, respectively). NNRTI resistance only was found in 17.4% of M12 patients (26/149) and 8.9% of M24 patients (17/192 [171/192] in the M12 and M24 groups, respectively). M184V was the most prevalent NRTI resistance mutation. Thymidine-analog mutations (TAMs) were found in 23.8% of M12 patients (29/ 122) with NRTI resistance and 45.7% of M24 patients (79/173) with NRTI resistance; the proportion of patients who accumulated ≥2 TAMs was also greater in the M24 group (7.4% vs 23.7%). Frequently observed TAMs included M41L, D67N, K70R, L210W, T215F/Y, and K219E/Q. In both groups, we found a low frequency of K65R (7/122 and 1/173 in the M12 and M24 groups, respectively; Table 3 ). For 2 patients, ART included tenofovir, while the 6 other patients received stavudine. Table 3) . The majority of patients had virus resistant to drugs they were receiving, most frequently lamivudine/emtricitabine, zidovudine, stavudine, or tenofovir for NRTIs and nevirapine/efavirenz for NNRTIs. However, few patients had resistance or reduced virus susceptibility to one or several ARVs they did not receive, including abacavir, didanosine, tenofovir, etravirine, and rilpivirine (Table 4) . These ARVs are likely to be used as second-line drugs in patients who accumulated multiple DRMs.
DISCUSSION
In this large and multisite study involving several African and Asian countries, we assessed the outcome of ARV treatment, using virological failure rate. We found substantial heterogeneity in treatment outcome, with variable levels of virological failure across clinics from the 7 countries, ranging between 2.9% and 20.6% in M12 patients and between 3.7% and 26.0% in M24 patients.
One key finding was the fact that, in few countries, we found low levels of virological failure (≤5%) after 12 or 24 months ART, and consequently <4% of patients from these sites had a resistant virus regardless of ART duration. This was unexpected because these results are similar if not better than those obtained from countries and groups, particularly industrialized countries and well-monitored study cohorts, in which patients received adequate treatment monitoring, including viral load assessment [12, 13] . In 3 countries (Cameroon, Senegal, and Vietnam), virological failure after 12 months was around 10% but was still better than recent reports from developing countries. Indeed, a review of 29 studies from sub-Saharan Africa showed an overall rate of virological failure after 12 months ART of 24% (2381/9794) [13, 23] . In these 3 countries, we also found reduced levels of virological failure at month 24 (10.3%-13.9%). The few previous studies assessing treatment outcome in this population group in developing countries generally reported failure rates of around 20% or more [10] [11] [12] [13] . This result should be considered with caution, however, because we did not evaluate loss to follow-up, ART cessation, and deaths, which may be more frequent at 24 months. In Cote d'Ivoire and Togo, however, we found high rates of virological failure (nearly 20% in the M12 group in both sites and almost 26% in the M24 group in Togo). The frequency of detection of drugresistant viruses was also high (10%-14% in M12 patients and up to 25% in the M24 group). These results indicate significant problems with ART management in these sites, and although they are alarming, they were unfortunately not exceptional, because similar findings were previously reported in Togo, where 30.8% of patients who received ART for 10-14 months had a detectable viral load (ie, ≥ 1000 copies/mL) and 24.5% had DRM [7] . A recent study from the Central African Republic reported a similar rate of virological failure (28.5%) after 24 months of ART [10] . In Cote d'Ivoire, we found a higher level of virological failure in M12 patients, compared with M24 patients (20.6% and 13.9%, respectively), and this was unusual since the reverse situation is generally observed. We have no explanation for this reverse trend but can exclude possible recruitment bias because patients in both groups were consecutively recruited. However, we cannot exclude possible correlation with sociopolitical events that the country has encountered during the past 10 years and that may have favored treatment interruptions, drug stock-outs, and limited access to treatment sites.
Our results, although not representative of whole-country performance, showed that treatment outcome using the public health approach varies significantly across settings. These differences in virological failure cannot be explained by the study populations, ARV regimens, or biological monitoring, which were almost similar in all sites. Also, HIV-1 genetic diversity could not explain these variations, since we observed significantly different results between Thailand and Vietnam, where only CRF01_AE viruses circulate, and important variations across sites in African countries where CRF02_AG predominates. Other factors should therefore be considered, and local programmatic factors or local management of clinics and healthcare centers are most likely associated with the heterogeneity of virological outcomes. Factors such as prescribing practices, proportion of patients lost to follow-up, punctual ARV drug pick-up, punctual appointment keeping, ARV stock-outs and shortages, and strategies to improve adherence have been shown to significantly impact treatment outcome [24] . Poor adherence has been associated with poor virologic response and subsequent emergence of resistant viruses [20] . Recent clinical trials from Uganda and Thailand have confirmed this important role of adherence in ART outcome and even showed the limited value of viral load testing when high level of adherence support is achieved [25, 25b] . We did not specifically assess site performances but found that in the 5 countries where we observed higher levels of failure, 18%-43% of patients with a viral load of ≥ 1000 copies/mL had virus with no resistance mutation, indicating adherence issues. Also, the similar rates of failure observed at 12 and 24 months in a few sites may indicate that for many patients, failure occurred early after treatment initiation and was thus likely to be associated with poor adherence. Our results indicate that the outcome of the current public health approach to scale-up treatment in the developing world cannot be predicted at a global level but should be evaluated in each treatment area. National programs are encouraged to conduct regular assessments of clinics by using the WHO early warning indicators tool [24] , which allows rapid identification of program factors that should be strengthened to prevent failure and premature emergence of resistant viruses. The high proportion of patients who did not respond to ART and had no resistant virus in this study advocates for the routine introduction of viral load testing in the current strategy to improve adherence and, more specifically, to prevent unnecessary switches to costly and less accessible second-line regimens, as previously described [11, 21, 22] . In this study, identified drug resistance mutations were essentially associated with prescribed ARV regimens. As expected, we found no patients with major PI resistance mutations, correlating with the absence of PIs in current first-line strategies. Resistance to NRTIs occurred at high frequency, with M184V being the most prevalent mutation, as already reported [26] . The proportion of patients with viruses containing ≥2 TAMs increased at month 24 in all countries, thus correlating with current knowledge on the fact that prolonged failure predicts TAMs accumulation [9, 15, 27] . The other NRTI resistance mutations, including K65R and Q151M, were hardly selected and emerged at a very low frequency, but we observed cases of stavudine-mediated K65R mutations, although less frequently than reported from other settings where subtype C is rare [28] . As expected, resistance to NNRTIs occurred at high frequency because of the low genetic barrier of these drugs. Interestingly, we found that virus in a significant proportion of M12 and M24 patients who had NNRTI resistance mutations accumulated mutations resulting in resistance to etravirine and/or rilpivirine, thus compromising options for second-and/or third-line treatment. We did not assess pretreatment drug resistance, but we showed in a study conducted in 2009 and involving the same countries except Togo that primary drug resistance was generally low (<5%) [29, 30] , although an increasing trend was recently reported in Cameroon [16] .
In conclusion, the current expansion of ART in developing countries still represents a critical challenge for national health systems, and regular evaluations are essential to identify achievements, weaknesses, and needs. Our results indicate that improving ART outcome in developing countries is still essential, but will not be achieved by only increasing access to virological monitoring as viral load. Better program management and implementation of actions to improve factors such as patient adherence, drug stock-outs, and loss to follow-up is essential. 
